Market Overview

UPDATE: Bank Of America Reiterates On BioCryst Pharmaceuticals Following EU Physicians Survey


In a report published Thursday, Bank of America analyst Steve Byrne reiterated an Underperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX), but lowered the price target from $9.00 to $8.00.

In the report, Bank of America noted, “We recently conducted a survey of 20 EU physicians treating HAE which follows our US survey in April. EU physicians seem less willing to switch from their current standard of care (Berinert, IV-based 2x/week), whereas US physicians would more readily switch from Cinryze (also IV-based 2x/week). Roughly half the doctors were familiar with BCRX's multiple pills/ 3x/day kallikrein inhibitor ('4161) and Dyax' 1-2x/month antibody (‘2930), and generally expected patients to prefer the less frequent injection therapy. However, a one pill per day therapy would be very attractive in both regions. We lower our PO to $8 from $9, due to lower EU pricing (see below), and are cautious ahead of Dyax's proof of concept data in mid-2015. We see potential upside from phase 2b for ‘4161 by YE 2015 (see below) and data for next gen products in 3Q15 (<$1/share in our valuation).”

BioCryst Pharmaceuticals closed on Wednesday at $10.58.

Latest Ratings for BCRX

Nov 2020Evercore ISI GroupInitiates Coverage OnOutperform
Jun 2020BTIGInitiates Coverage OnNeutral
May 2020BarclaysUpgradesEqual-WeightOverweight

View More Analyst Ratings for BCRX
View the Latest Analyst Ratings


Related Articles (BCRX)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Price Target Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at